COMPANY PROFILE

Emergence Therapeutics

Explore full profile

European biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers

Duisburg, GermanyFounded 2019Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Emergence Therapeutics

Emergence Therapeutics is a biotechnology company focused on developing Antibody-Drug Conjugates (ADCs) for the treatment of hard-to-treat cancers. The company's lead program, ETx 22, targets Nectin 4 and aims to deliver higher efficacy with lower risk of off-target side effects and the ability to avoid tumor resistance. ETx 22 utilizes an innovative linker and payload technology to achieve these goals. Emergence Therapeutics serves patients with difficult-to-treat cancers and operates in the biopharmaceutical market. The business model revolves around the development and commercialization of first or best-in-class ADCs, driven by therapeutic need. Revenue is generated through the development and potential future sales of these ADCs, as well as possible partnerships and licensing agreements.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2019
Headquarters: Duisburg, Germany
Employees: 13
Open positions: None listed
Dealroom signal: 59.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, radar de l'innovation, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jun 2023	$0	—	Eli Lilly	↗
SERIES AOther financing	Dec 2021	$96M	$383M	Hadean Ventures · Gründerfonds Ruhr · Surveyor Capital · Pontifax Funds	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Emergence Therapeutics website traffic

Latest recorded traffic for Emergence Therapeutics is 310 monthly website visits, up 106.7% over the last three months. Emergence Therapeutics's team grew 0% over the past year.

Latest monthly visits310 3-month web change+106.7% 1-year team growth0%

Monthly website visitsOct 2020–Jun 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed	—	$1.1M	$4.4M
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational
ONOncoVITAPreclinical stage biotech company pioneering the development of oncolytic viruses to address unmet medical need	Paris, France	Operational
ATApmonia TherapeuticsApmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies	Reims, France	Operational
HBHoning BiosciencesBio-therapeutics company that develops and improves cell-based therapies	Paris, France	Operational
TOTollysDevelopment of innovative immunotherapies targeting cancer through the modulation of the TLR3 receptor	Lyon, France	Closed
PHPhost’inA biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors	Montpellier, France	Operational
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational